EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites).
Objectives:
- Comparison of antimicrobial susceptibility using disc-diffusion method
- Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients
Isolates (as specified in the observational plan) from hospitalised patients
Isolates obtained from outpatients will not be included for the study. Isolates from repeat
cultures performed during in-patient follow-up that were previously recruited into the
study will be excluded.
Isolates identified as commensals or contaminants will be excluded
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns | |||
| Official Title | Expert Group On Antibiotic Susceptibility Testing [EGAST] 2008: A Non-Interventional, Multicenter In-Vitro Study To Evaluate The Prevalence Of Beta-Lactamase Producing Strains Among Clinical Isolates Obtained From Hospital In-Patients And Comparison Of Antimicrobial Susceptibility Using Disc-Diffusion Method | |||
| Brief Summary | EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites). Objectives:
| |||
| Detailed Description | n/a n/a | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Other Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | Isolates from hospitalised patients | |||
| Condition | Infection | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | Not Provided | |||
| Publications * | Not Provided | |||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 2039 | |||
| Original Estimated Enrollment | 2000 | |||
| Actual Study Completion Date | September 2009 | |||
| Actual Primary Completion Date | September 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria: Isolates (as specified in the observational plan) from hospitalised patients Exclusion Criteria: Isolates obtained from outpatients will not be included for the study. Isolates from repeat cultures performed during in-patient follow-up that were previously recruited into the study will be excluded. Isolates identified as commensals or contaminants will be excluded | |||
| Sex/Gender |
| |||
| Ages | Child, Adult, Older Adult | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | India | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00728624 | |||
| Other Study ID Numbers | A1891005 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | March 2017 | |||
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
